BrightPath Biotherapeutics Co., Ltd. (TYO:4594)
Japan · Delayed Price · Currency is JPY 51.00
0.00 (0.00%)
Aug 6, 2026, 1:46 PM JST
TYO:4594 Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
| 0.08 | 1.13 | 0.07 | 354 | 529 | |
Revenue Growth | -92.59% | 1473.61% | -99.98% | -33.08% | - |
Cost of Revenue | 0.03 | 0.03 | 0.02 | 316 | 525 |
Gross Profit | 0.06 | 1.1 | 0.05 | 38 | 4 |
Selling, General & Admin | 1,295 | 1,162 | 1,155 | 344 | 299 |
Research & Development | - | - | - | 1,253 | 816 |
Operating Expenses | 1,295 | 1,162 | 1,155 | 1,600 | 1,118 |
Operating Income | -1,295 | -1,161 | -1,155 | -1,562 | -1,114 |
Interest & Investment Income | 0.02 | 0.07 | 0.01 | - | - |
Currency Exchange Gain (Loss) | -6.68 | 2.25 | -2.66 | - | -1 |
Other Non Operating Income (Expenses) | -9.89 | -4.38 | -1.2 | -11 | -1 |
EBT Excluding Unusual Items | -1,312 | -1,163 | -1,159 | -1,573 | -1,116 |
Gain (Loss) on Sale of Assets | 0.4 | - | - | - | - |
Asset Writedown | -9.4 | -1.37 | -7.25 | - | - |
Other Unusual Items | 18.02 | 15.11 | - | - | - |
Pretax Income | -1,303 | -1,149 | -1,166 | -1,573 | -1,116 |
Income Tax Expense | 2.42 | 1.9 | 1.9 | 5 | 5 |
Earnings From Continuing Operations | -1,305 | -1,151 | -1,168 | -1,578 | -1,121 |
Minority Interest in Earnings | - | - | - | 1 | 8 |
Net Income | -1,305 | -1,151 | -1,168 | -1,577 | -1,113 |
Net Income to Common | -1,305 | -1,151 | -1,168 | -1,577 | -1,113 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 112 | 82 | 64 | 38 | 34 |
Shares Outstanding (Diluted) | 112 | 82 | 64 | 38 | 34 |
Shares Change | 36.87% | 27.03% | 67.81% | 12.41% | - |
EPS (Basic) | -11.70 | -14.12 | -18.21 | -41.25 | -32.72 |
EPS (Diluted) | -11.70 | -14.12 | -18.21 | -41.25 | -32.72 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
Free Cash Flow | -1,366 | -1,252 | -1,163 | -1,699 | -1,164 |
Free Cash Flow Per Share | -12.25 | -15.36 | -18.13 | -44.44 | -34.22 |
Gross Margin | 65.48% | 97.18% | 75.00% | 10.73% | 0.76% |
Operating Margin | -1541666.67% | -102464.08% | -1604276.39% | -441.24% | -210.59% |
Profit Margin | -1553513.09% | -101601.85% | -1622336.11% | -445.48% | -210.40% |
Free Cash Flow Margin | -1626716.67% | -110479.17% | -1615436.11% | -479.94% | -220.04% |
EBITDA | - | - | -1,155 | -1,489 | -1,073 |
EBITDA Margin | - | - | - | - | -202.84% |
D&A For EBITDA | - | - | 0.4 | 73 | 41 |
EBIT | -1,295 | -1,161 | -1,155 | -1,562 | -1,114 |
EBIT Margin | - | - | - | - | -210.59% |